What are the specific specifications of Quizartinib?

Quizartinib (Quizartinib) is a new oral tyrosine kinase inhibitor that mainly targets FLT3-ITD mutated acute myeloid leukemia (AML). It is one of the precision treatment drugs that has attracted much attention in the field of hematological tumors in recent years. This drug inhibits the proliferation and survival of leukemia cells by inhibiting abnormal signaling of the FLT3 receptor, which has important targeted therapeutic significance. According to the current public information, the common drug specifications of Quizartinib mainly include 17.7mg packed with 28 tablets and 26.5mg packed with 56 tablets. Such dosage settings are mainly to meet the individualized dosage needs of different patients during the treatment cycle.

Quizatinib’s specification design features precise dosing, especially during dose escalation or maintenance treatment phases. Flexible dose combinations can improve the safety and compliance of treatment. The starting dose of 17.7mg is usually used for initial induction therapy or patients with weak liver and kidney function, while 26.5mg is mostly used for dose adjustment or maintenance therapy, helping doctors to conduct refined management based on the patient's tolerance and efficacy. The drug's tablet form is convenient for oral administration and is convenient for home administration and long-term use.

Drug specifications not only affect patients' medication convenience, but also are related to the efficiency of treatment plan implementation. This dual-strength combination mode of quizartinib also reflects its flexibility in clinical use, allowing doctors to more safely conduct individualized treatments when facing patients with different physiological states, complications or concomitant medications. At present, Quizartinib has been approved by regulatory agencies in many countries such as the United States, Japan and other places, indicating that its drug specifications and dosage design have been strictly verified and it has stable pharmacokinetic and pharmacodynamic properties.

Understanding the specific dosage form of the drug is not only helpful to improve treatment compliance, but also helps patients to rationally plan the medication cycle and monitor treatment response, which is an integral part of targeted therapy that cannot be ignored.

Reference materials:https://go.drugbank.com/drugs/DB12874